دورية أكاديمية
Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
| العنوان: | Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. |
|---|---|
| المؤلفون: | Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele M, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin M, Mayer J, Babcock HM, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani J, Schrag S |
| مؤلفون مشاركون: | Vaccine Effectiveness Among Healthcare Personnel Study Team |
| المصدر: | MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2021 May 21; Vol. 70 (20), pp. 753-758. Date of Electronic Publication: 2021 May 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Atlanta, GA : U.S. Centers for Disease Control Original Publication: [Atlanta] U. S. Dept. of Health, Education, and Welfare, Public Health Service, Center for Disease Control. |
| مواضيع طبية MeSH: | COVID-19/*prevention & control , COVID-19 Vaccines/*immunology , Health Personnel/*statistics & numerical data , Occupational Diseases/*prevention & control, Adult ; Aged ; COVID-19/epidemiology ; COVID-19 Testing ; COVID-19 Vaccines/administration & dosage ; Case-Control Studies ; Female ; Humans ; Immunization Schedule ; Male ; Middle Aged ; Occupational Diseases/epidemiology ; United States/epidemiology ; Young Adult |
| مستخلص: | Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection. Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Deverick Anderson is the owner of Infection Control Education for Major Sports, LLC, and reports grants from the Agency for Healthcare Research and Quality and personal fees from UpToDate, outside the submitted work. Ghinwa Dumyati reports grants from Pfizer and personal fees from Roche Diagnostics. Gregory Moran reports grants from I-Mab Biopharma and BeiGene and personal fees from Light AI. Mark Steele reports personal fees from Light AI, during the conduct of the study. No other potential conflicts of interest were disclosed. |
| References: | MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500. (PMID: 33793460) N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250) MMWR Morb Mortal Wkly Rep. 2020 Sep 25;69(38):1364-1368. (PMID: 32970661) Lancet. 2021 May 8;397(10286):1725-1735. (PMID: 33901423) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660. (PMID: 33382671) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) |
| معلومات مُعتمدة: | U01 CK000480 United States CK NCEZID CDC HHS |
| فهرسة مساهمة: | Investigator: A Yousaf, CDC COVID-19 Response Team.; Y Chung, CDC COVID-19 Response Team.; J Onukwube, CDC COVID-19 Response Team.; W Xing, CDC COVID-19 Response Team.; B Clinansmith, University of Iowa, Iowa City, Iowa.; L Uribe, Olive View-University of California Los Angeles Medical Center, Los Angeles, California.; KE Poronsky, Baystate Medical Center, Springfield, Massachusetts.; DM Hashimoto, Brigham and Women's Hospital, Boston, Massachusetts.; M Bahamon, Jackson Memorial Hospital, Miami, Florida.; M St Romain, Louisiana State University, New Orleans, Louisiana.; E Kean, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.; A Stubbs, Truman Medical Center, Kansas City, Missouri.; S Roy, University of Chicago, Chicago, Illinois.; G Volturo, University of Massachusetts, Worcester, Massachusetts.; J Galbraith, University of Mississippi, Jackson, Mississippi.; JC Crosby, University of Alabama at Birmingham, Birmingham, Alabama.; MR Fuentes, University of Washington, Seattle, Washington.; M Mulrow, Valleywise Health Medical Center, Phoenix, Arizona.; J Lee, California Emerging Infections Program, Oakland, California.; H Johnston, Colorado Department of Public Health and Environment, Denver, Colorado.; A Hansen, Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut.; SK Fridkin, Georgia Emerging Infections Program, Atlanta, Georgia, and Emory University School of Medicine, Atlanta, Georgia.; LE Wilson, Department of Emergency Health Services, University of Maryland, Baltimore County, Baltimore Maryland.; S Lovett, Minnesota Emerging Infections Program, Minnesota Department of Health, St. Paul, Minnesota.; M Christian, University of New Mexico, Albuquerque, New Mexico, and New Mexico Emerging Infections Program, Santa Fe, New Mexico.; C Myers, University of Rochester Medical Center/New York State-Rochester Emerging Infections Program,, Rochester, New York.; VLS Ocampo, Public Health Division, Oregon Health Authority, Portland, Oregon.; K Talbot, Vanderbilt University Medical Center, Nashville, Tennessee.; J Seidelman, Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine, Durham, North Carolina.; AM Milstone, Johns Hopkins School of Public Health, Baltimore, Maryland.; M Hayden, Department of Medicine, Rush University, Medical Center, Chicago, Illinois.; M Samore, University of Utah, VA Salt Lake City Health Care System, Salt Lake City, Utah.; JH Kwon, Washington University School of Medicine, St. Louis, Missouri.; D Shirley, University of Wisconsin-Madison, Madison, Wisconsin.; D Dillard, Southcentral Foundation, Anchorage, Alaska.; J Dobson, Yukon-Kuskokwim Health Corporation, Bethel, Alaska. |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20210520 Date Completed: 20210521 Latest Revision: 20220716 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8136422 |
| DOI: | 10.15585/mmwr.mm7020e2 |
| PMID: | 34014909 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!